| Market Cap | 6.54M | P/E | - | EPS this Y | 78.50% | Ern Qtrly Grth | - |
| Income | -12.57M | Forward P/E | -1.00 | EPS next Y | 64.20% | 50D Avg Chg | -6.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -76.00% |
| Dividend | N/A | Price/Book | 0.46 | EPS next 5Y | - | 52W High Chg | -96.00% |
| Recommedations | 1.50 | Quick Ratio | 5.39 | Shares Outstanding | 3.41M | 52W Low Chg | 20.00% |
| Insider Own | 0.33% | ROA | -66.09% | Shares Float | 2.27M | Beta | 2.22 |
| Inst Own | 38.57% | ROE | -113.79% | Shares Shorted/Prior | 50.31K/115.91K | Price | 0.30 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 725,469 | Target Price | 18.50 |
| Oper. Margin | - | Earnings Date | Nov 11 | Volume | 119,607 | Change | -3.88% |
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
| Roth MKM | Buy | Feb 20, 24 |